Eric L Smith

List of Publications by Year
in descending order

55 papers	2,394 citations	361045 20 h-index	223531 46 g-index
58 all docs	58 docs citations	58 times ranked	4364 citing authors

#	Article	IF	Citations
1	CD19-directed chimeric antigen receptor T cell therapy in WaldenstrÃ¶m macroglobulinemia: a preclinical model and initial clinical experience. , 2022, 10, e004128.		18
2	Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. Clinical Cancer Research, 2022, 28, 2160-2166.	3.2	2
3	Activation of Tumor-Cell STING Primes NK-Cell Therapy. Cancer Immunology Research, 2022, 10, 947-961.	1.6	22
4	Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study. Leukemia and Lymphoma, 2022, 63, 2760-2761.	0.6	1
5	Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twiceâ€weekly carfilzomib (45 and 56â€‰mg/m‹sup›2‹/sup›) in combination with lenalidomide and dexamethasone. American Journal of Hematology, 2021, 96, E193-E196.	2.0	10
6	Chimeric Antigen Receptorâ€“Modified Immune Effector Cell Therapies. Cancer Journal (Sudbury, Mass), 2021, 27, 90-91.	1.0	0
7	Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy. Clinica Chimica Acta, 2021, 516, 136-141.	0.5	7
8	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematology,the, 2021, 8, e422-e432.	2.2	50
9	Finding the Optimal Partner to Pair with Bispecific Antibody Therapy for Multiple Myeloma. Blood Cancer Discovery, 2021, 2, 297-299.	2.6	3
10	Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection. Molecular Therapy, 2021, 29, 3398-3409.	3.7	10
11	Phase I First-in-Class Trial of MCARH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma. Blood, 2021, 138, 827-827.	0.6	23
12	Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 58-65.	2.0	8
13	Future prospects of chimeric antigen receptor Tâ€cell therapy for multiple myeloma. Advances in Cell and Gene Therapy, 2020, 3, e72.	0.6	0
14	Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 198-200.	0.2	17
15	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. , 2020, 8, e000734.		27
16	Future of CAR T cells in multiple myeloma. Hematology American Society of Hematology Education Program, 2020, 2020, 272-279.	0.9	22
17	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. Blood Cancer Discovery, 2020, 1, 234-243.	2.6	46
18	Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Advances, 2020, 4, 3776-3787.	2.5	162

#	Article	IF	Citations
19	Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 2040-2046.	2.0	1
20	Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escapeâ€"Driven Relapse in Multiple Myeloma. Blood Cancer Discovery, 2020, 1, 146-154.	2.6	114
21	Comparison of MALDIâ€TOF mass spectrometry analysis of peripheral blood and bone marrowâ€based flow cytometry for tracking measurable residual disease in patients with multiple myeloma. British Journal of Haematology, 2020, 189, 904-907.	1.2	40
22	CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. Radiology, 2020, 295, 606-615.	3.6	73
23	Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2020, 26, 1394-1401.	2.0	8
24	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. Blood, 2020, 136, 18-19.	0.6	0
25	BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy. Cancer Immunology Research, 2019, 7, 1047-1053.	1.6	59
26	GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Science Translational Medicine, 2019, 11, .	5.8	229
27	Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells. Cancer Journal (Sudbury, Mass), 2019, 25, 208-216.	1.0	10
28	VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis. Blood, 2019, 134, 1835-1835.	0.6	7
29	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. Blood, 2019, 134, 3127-3127.	0.6	2
30	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study. Blood, 2019, 134, 862-862.	0.6	34
31	MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy. Blood, 2019, 134, 4377-4377.	0.6	2
32	Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients with Multiple Myeloma. Blood, 2019, 134, 3060-3060.	0.6	0
33	Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T). Blood, 2019, 134, 4455-4455.	0.6	0
34	An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma. Blood, 2019, 134, 5554-5554.	0.6	0
35	Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. Leukemia and Lymphoma, 2018, 59, 1981-1985.	0.6	16
36	CARs and other T cell therapies for MM: The clinical experience. Best Practice and Research in Clinical Haematology, 2018, 31, 147-157.	0.7	21

#	Article	IF	Citations
37	Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector. Molecular Therapy, 2018, 26, 1447-1456.	3.7	77
38	CAR T cell therapy for multiple myeloma: where are we now and where are we headed?. Leukemia and Lymphoma, 2018, 59, 2056-2067.	0.6	50
39	Identifying Ultra-High Risk Smoldering Multiple Myeloma. Blood, 2018, 132, 3192-3192.	0.6	1
40	Bone Marrow-Based and Longitudinal Blood-Based MRD Tracking in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd): A Correlative and Clinical Phase II Study. Blood, 2018, 132, 3281-3281.	0.6	4
41	Depth of Response and Outcomes in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Blood, 2018, 132, 4619-4619.	0.6	4
42	Continuous Mobile Wearable Bio-Monitoring of Newly Diagnosed Multiple Myeloma Patients Undergoing Initial Chemotherapy. Blood, 2018, 132, 4751-4751.	0.6	1
43	MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with Lenalidomide and Dexamethasone. Blood, 2018, 132, 1983-1983.	0.6	2
44	Intestinal Microbiota Composition Prior to CAR T Cell Infusion Correlates with Efficacy and Toxicity. Blood, 2018, 132, 3492-3492.	0.6	13
45	Capture Rate of the Adaptive Next Generation Sequencing VDJ Assay in Multiple Myeloma. Blood, 2018, 132, 3184-3184.	0.6	3
46	Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial. Blood, 2018, 132, 959-959.	0.6	71
47	Treatment Outcomes in Monoclonal Immunoglobulin Deposition Disease (MIDD): A Two Center Experience. Blood, 2018, 132, 5591-5591.	0.6	0
48	Novel Immunotherapies for Multiple Myeloma. Current Hematologic Malignancy Reports, 2017, 12, 344-357.	1.2	30
49	Development and Evaluation of a Human Single Chain Variable Fragment (scFv) Derived Bcma Targeted CAR T Cell Vector Leads to a High Objective Response Rate in Patients with Advanced MM. Blood, 2017, 130, 742-742.	0.6	92
50	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature Reviews Clinical Oncology, 2016, 13, 273-290.	12.5	909
51	CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2016, 22, 258-267.	2.0	21
52	Whole Exome Sequencing from Nine Independent Sites of Extraosseous Disease in a Single Patient with Relapsed Multiple Myeloma Show That Extramedullary Disease Arise through a Combination of Branched and Parallel Evolution. Blood, 2016, 128, 2090-2090.	0.6	0
53	CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?. Immunotherapy, 2015, 7, 545-561.	1.0	26
54	Presence of PD-1 Expressing T Cells Predicts for Inferior Overall Survival in Newly Diagnosed Multiple Myeloma. Blood, 2015, 126, 1785-1785.	0.6	4

#	Article	IF	Citations
55	Harnessing the immune system for cancer therapy. Current Opinion in Oncology, 2014, 26, 600-607.	1.1	25